Insilico Medicine has closed a $255 million oversubscribed Series C round led by Warburg Pincus. Since its inception in 2014 the company has raised over $310 million and received multiple industry awards. Insilico Medicine has also published over 130 peer-reviewed papers and has applied for over 30 patents. Proceeds from this round will be used to advance the company’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.
Other investors who participated in this round included Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners.
“The artificial intelligence technologies we invented are now demonstrating impressive results and delivering valuable and absolutely novel therapeutic assets with high probability of clinical success. We are proud to have gained recognition and investment from some of the world’s most reputable investors with strong expertise in the biopharmaceutical industry. With their support, we will continue to innovate and bring revolutionary solutions to the pharmaceutical industry.”
Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine
As a pioneer and leader in the industry, Insilico Medicine has built a strong drug discovery and drug development team, a broad distributed discovery partner network, and initiated multiple internal therapeutic programs. In 2019 the Company demonstrated the first case of AI identifying a novel target for a major pulmonary disease, generating novel molecules for that novel target, and completing the preclinical experiments required to nominate a preclinical candidate in under 18 months.
Insilico Medicine also developed the AI-powered drug discovery platform consisting of PandaOmics™ AI-powered novel target discovery engine, Chemistry42™ deep generative reinforcement learning system allowing for de-novo design of novel molecules with the desired properties that do not exist in the known chemical space, and InClinico™, which predicts clinical trial outcomes. Since the launch of Insilico Medicine’s Chemistry42 in September 2020, 7 out of 30 top pharmaceutical companies deployed its software, including Merck KGaA and UCB.
Since the previous round of financing, Insilico Medicine is making its technologies available for licensing for the leading pharmaceutical and biotechnology companies looking to gain a head start in AI and accelerate their drug discovery programs. It has collaborated with first-in-class biopharmaceutical companies, including Pfizer, Astellas, Johnson & Johnson, Taisho, and many others, with multiple partners reaching major milestones. Insilico Medicine also exclusively partnered with the main innovative sustainable agriculture company, Syngenta, on the discovery of novel molecules for sustainable regenerative farming.
Insilico Medicine’s AI system revealed a novel wide-indication target, and a corresponding drug candidate in under 18 months and at roughly 1/10th of the cost typically associated with similar programs.
Insilico Medicine develops AI systems that utilize deep generative models, reinforcement learning (RL), transformers, and other modern machine learning techniques for the generation of new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trials outcomes. The company integrates two business models; providing AI-powered drug discovery services and software through its Pharma.AIplatform and developing its own pipeline of preclinical programs.
About Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm focused on growth investing. The firm has more than $60 billion in private equity assets under management. The firm’s active portfolio of more than 200 companies is highly diversified by stage, sector, and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised 19 private equity funds, which have invested more than $90 billion in over 930 companies in more than 40 countries. Since entering China in 1994, Warburg Pincus has invested nearly $14 billion in nearly 140 companies in the region. Warburg Pincus is one of the most active investors in the China healthcare industry, having invested more than $1.85 billion in the sector.